{"id":"NCT02971891","sponsor":"Maruho Co., Ltd.","briefTitle":"A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts","officialTitle":"A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01","primaryCompletion":"2018-04-16","completion":"2018-07-10","firstPosted":"2016-11-23","resultsPosted":"2023-09-14","lastUpdate":"2023-09-14"},"enrollment":484,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cutaneous Common Warts"],"interventions":[{"type":"DRUG","name":"CLS006 (Furosemide) Topical Gel","otherNames":[]},{"type":"DRUG","name":"Vehicle Topical Gel","otherNames":[]}],"arms":[{"label":"CLS006 (Furosemide)","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects â‰¥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).","primaryOutcome":{"measure":"Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation.","timeFrame":"Week 18","effectByArm":[{"arm":"CLS006 (Furosemide)","deltaMin":32,"sd":null},{"arm":"Vehicle","deltaMin":24,"sd":null}],"pValues":[{"comp":"OG000","p":"0.1789"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":246},"commonTop":["Upper respiratory tract infection","Headache","Sinusitis"]}}